ABSTRACT
Objective: To analyze the phytochemical compounds and to investigate the bio-toxic efficacy of various solvent extracts of Plectranthus amboinicus against mosquito larvae activity and lethality on non-targeting organisms. Methods: The methanol, ethyl acetate, hexane, and aqueous extracts of Plectranthus amboinicus were subjected to analyze the mosquitocidal activity against the dengue vector, Aedes aegypti and toxicity assays on zebra fish and brine shrimp. Three replications were performed, and negative control was also maintained. Amongst, ethyl acetate extract of Plectranthus amboinicus was chosen for the determination of bio-active compounds. Results: The mosquitocidal assays of methanol and ethyl acetate extracts of Plectranthus amboinicus showed the maximal activity with minimal concentration against the 4th instar mosquito-larvae of Aedes aegypti through the following lethal concentration (LC50 and LC90) values: 53.36 & 92.51 μg/mL and 13.64 & 86.09 μg/mL, respectively. In addition, the plant extracts showed no toxicity on zebra fish embryo and brine shrimp assays. The gas-chromatography analysis of the ethyl acetate extract of Plectranthus amboinicus revealed the presence of seven different compounds. Among them, PAEA-fraction 60 contained a major active bioactive compound, hexadecanoic acid, methyl ester (270.0). Conclusions: Plectranthus amboinicus possesses mosquitocidal properties and could be used as a potential alternative source for preparing the mosquitocidal agents.
ABSTRACT
Breast cancer is the second most common malignant disease affecting Indian women and is the leading cause of cancer-related mortality. MicroRNAs (miRNAs) are remarkably stable in blood, which makes them novel and promising biomarkers for cancer detection and diagnosis. In this study, we investigated whether expression levels of circulating specific miRNAs, such as microRNA-21 (miR-21) and microRNA-146a (miR-146a) could be used as potential biomarkers in plasma of breast cancer patients and healthy individuals. We compared the expression levels of breast cancer associated specific miRNAs — miR-21 and miR-146a in plasma samples of histopathologically reported 14 patients (aged 35-61 yrs) with breast cancer and an additional 8 healthy volunteers (aged 35-54 yrs). The miRNA expression level was determined by TaqMan quantitative PCR (qPCR) assay. The miRNA expression level of each sample was normalized to that of miR-16 as reference and expressed as relative expression (2-Ct). Our results showed that the circulating level of miR-21 and miR-146a were significantly higher in plasma samples of breast cancer patients, when compared to those of healthy controls (p<0.0004 and p<0.005, respectively). Thus, analyzing expression of miR-21 and miR-146a from plasma samples of breast cancer patients might be useful in the diagnosis of breast cancer. However, further studies with larger number of patients and control individuals are needed to confirm the results.